Literature DB >> 30195571

Tofacitinib for the treatment of alopecia areata in preadolescent children.

Brittany G Craiglow1, Brett A King2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30195571     DOI: 10.1016/j.jaad.2018.08.041

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  7 in total

Review 1.  Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.

Authors:  Cheng Zhou; Xiangqian Li; Chen Wang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-17       Impact factor: 8.667

2.  An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature.

Authors:  Rachel Berbert Ferreira; Sineida Berbert Ferreira; Morton Aaron Scheinberg
Journal:  Clin Case Rep       Date:  2019-11-21

Review 3.  Treatment of pediatric alopecia areata: A systematic review.

Authors:  Virginia R Barton; Atrin Toussi; Smita Awasthi; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2021-04-30       Impact factor: 15.487

4.  The Role of Tofacitinib in the Management of Alopecia Totalis.

Authors:  Carlos Hernandez-Montoya; Ricardo Ruiz-Villaverde
Journal:  Sultan Qaboos Univ Med J       Date:  2019-05-30

Review 5.  Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Authors:  Ana M Montilla; Francisco Gómez-García; Pedro J Gómez-Arias; Jesús Gay-Mimbrera; Jorge Hernández-Parada; Beatriz Isla-Tejera; Juan Ruano
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-13

6.  Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient.

Authors:  Danielle M Peterson; Matthew D Vesely
Journal:  JAAD Case Rep       Date:  2020-03-24

Review 7.  An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.

Authors:  Maddison Lensing; Ali Jabbari
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.